Andrew King
Equibles does not estimate personal net worth.
Get an email with a short summary when Jade Biosciences, Inc. publishes a filing, an earnings call transcript or a press release.
Get JBIO alertsAbout Andrew King
Andrew King is recorded as CTO at Jade Biosciences, Inc. (JBIO) since April 28, 2025. Jade Biosciences, Inc. reported in an 8-K filed April 22, 2026 that Andrew King was appointed President, Research & Development, effective April 18, 2026. Jade Biosciences, Inc. reported in an 8-K filed May 1, 2025 that Andrew King was appointed the Company's Chief Scientific Officer & Head of Research and Development, effective April 28, 2025. The proxy statement of Jade Biosciences, Inc. reports total compensation of $4,541,804 for Andrew King in fiscal 2025, including a base salary of $507,301. Disclosed compensation is on record for 2 fiscal years. Jade Biosciences, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Jade Biosciences, Inc. includes Tom Frohlich (CEO and Board Member), Eric Dobmeier (Chairman and Board Member), Bradford Dahms (CFO) and 7 others.
“On April 18, 2026, the Board of Directors of Jade Biosciences, Inc. (the "Company") appointed Andrew King, BVMS, Ph.D. as the Company's President, Research & Development, effective as of April 18, 2026.”
“On April 28, 2025, the Board appointed Tom Frohlich as the Company's Chief Executive Officer, Jonathan Quick as the Company's Senior Vice President, Finance and Treasurer, Andrew King as the Company's Chief Scientific Officer & Head of Research and Development, Hetal Kocinsky as the Company's Chief Medical Officer and Elizabeth Balta as General Counsel and Corporate Secretary, each to serve at the discretion of the Board.”
Affiliation history
-
Current
2025-04-28–present
-
Jade Biosciences, Inc. (JBIO)
Proxy statement
CurrentStart not stated–present
Last confirmed April 28, 2026
Company network
Leadership on record at Jade Biosciences, Inc.
- Tom Frohlich CEO, Board Member
- Eric Dobmeier Chairman, Board Member
- Bradford Dahms CFO
- Benjamin T. Dake COO
- Elizabeth Balta General Counsel
- Christopher Cain Board Member
- Continuing Directors Board Member
- Donald J. Santel Board Member
- Erin Lavelle Board Member
- Habib J. Dable Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Jade Biosciences, Inc. (JBIO) | President, Research and Development | $507,301 | $4,541,804 |
| 2024 | Jade Biosciences, Inc. (JBIO) | President, Research and Development | $313,636 | $751,605 |